
H.C. Wainwright reiterates a Buy rating on Enanta (ENTA) with a $20 price target following the fiscal Q4 report. While the Phase 1 data for oral KIT inhibitor EDP-978 shifted
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals | 8.23 | -3.26 | -28.36% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.23 | -28.36% |

H.C. Wainwright reiterates a Buy rating on Enanta (ENTA) with a $20 price target following the fiscal Q4 report. While the Phase 1 data for oral KIT inhibitor EDP-978 shifted

Another AI-trade rout on Monday has pressured the tech-heavy Nasdaq Composite by 2.5% to its lowest level since post-midterm Thursday, with the index now within a percentage point of 7-month

Reports Q4 revenue $12.9M, consensus $15.72M. “During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial

Enanta Pharmaceuticals (ENTA) is scheduled to report 4th quarter earnings on 11/16/2026, after the market closes. Regarding Q4 estimates, Wall Street analysts expect Enanta Pharmaceuticals to post earnings of -$0.72

Enanta Pharmaceuticals ( ($ENTA) ) has issued an update. Enanta Pharmaceuticals has been pursuing a patent infringement case in the Unified Patent Court of the European Union against Pfizer Inc.

The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). On October 28, 2026, Enanta Pharmaceuticals announced that longtime President and Chief Executive Officer Jay R. Luly, Ph.D., age

Enanta (ENTA) Pharmaceuticals announces that Jay Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company.

Enanta (ENTA) Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from

Enanta Pharmaceuticals (ENTA) has disclosed a new risk, in the Regulation category. Enanta Pharmaceuticals faces broad and ongoing uncertainties, as the risk landscape described in its 2025 Form 10-K continues

Reports Q3 revenue $14.4M, consensus $16.8M. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 8, 2027After Close | $253.10M | $-0.53 | $15.94M | 0.10 | -3.71 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.